Acquisition gives SERB a commercial presence in the US and expands critical care portfolioLearn More
Methotrexate (MTX) is an antifolate therapeutic agent that possesses potent anticancer activity against both solid tumors and leukemia.2 High-dose methotrexate (HDMTX), defined as a dose higher than 500 mg/m2, is used to treat a range of adult and childhood cancers, including1,2:
For patients with normal renal function, HDMTX may be safely administered with appropriate supportive care; however, despite standard support measures, HDMTX carries the risk of severe toxicity1,2:
When renal dysfunction occurs and other toxicities are present, standard doses of leucovorin may no longer be an effective rescue intervention.3
Administer Voraxaze® to quickly lower MTX levels and avoid further systemic damage.